Dr Reddy’s accomplices with RDIF to convey 100 million doses of Sputnik V antibody in India

Dr Reddy’s accomplices with RDIF to convey 100 million doses of Sputnik V antibody in India


  • Post By : Kumar Jeetendra

  • Source: PTI

  • Date: 16 Sep,2020

Hyderabad, Sep 16 (PTI) The Russian Direct Investment Fund (RDIF), Russias autonomous wealth finance, and Dr Reddys Laboratories Ltd. have agreed to collaborate on clinical trials and supply of Sputnik V vaccine in India. Upon regulatory approval in India, RDIF shall supply to Dr. Reddys 100 million doses of the vaccine, Dr Reddys stated in a release on Wednesday. The Sputnik V vaccine, which is based on well-studied human adenoviral vector system with proven security, is undergoing clinical trials for the coronavirus pandemic, ” said. Deliveries could potentially begin in late 2020, subject to completion of successful trials and registration of the vaccine by regulatory authorities in India, the release stated. Kirill Dmitriev, CEO of the Russian Direct Investment Fund, stated RDIF is very pleased to partner with Dr. Reddys in India.

Dr. Reddys has experienced a well established and respected presence in Russia for over 25 years and is one of the major pharmaceutical firms in India, he said. “India is amongst most severely impacted countries from COVID-19 and we believe our human adenovirus double vector platform will provide a safe and scientifically validated option to India from the struggle against COVID 19,” the release quoted Dmitriev as saying. RDIF partners will receive an effective and safe drug to fight the coronavirus.

The platform of human adenoviral vectors, which is the crux of the Russian vaccine, has been tested in more than 250 clinical studies over decades, and it’s been found safe with no potential negative long-term effects, Dmitriev said. G V Prasad, Co-Chairman and Managing Director of Dr. Reddys Laboratories said his company is pleased to partner with RDIF to deliver the vaccine to India. “The Phase I and II clinical trials have shown promising results. We will be running Phase-III trials in India to ensure efficacy and safety for the Indian population and to meet the demands of the Indian authorities. Sputnik V vaccine could offer a plausible option in our struggle against COVID 19 in India, he said.

About Author